Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chengrui Fu
Observed names:
CHENGRUI FU,
Cheng-Rui Fu
Institutions:
Shandong Tumor Hospital,
Shandong First Medical University
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Yuhuangding Hospital,
University of Jinan,
Shandong Tumor Hospital,
Shandong First Medical University,
Tianjin Medical University
show all 6
ORCID:
0009-0000-8449-7111
Observed ORCID:
0009-0000-8449-7111
OpenAlex ID:
A5109709012
Thoracic Radiotherapy Improves the Survival in Patients With EGFR -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
2024
·
Hongfu Sun
, Minghao Li
, et al.
·
Journal of Clinical Oncology
·
78
The expression of miR-21 and miR-375 predict prognosis of esophageal cancer
2014
·
Chengrui Fu
, Wei Dong
, et al.
·
Biochemical and Biophysical Research Communications
·
38
Prognostic significance of miR-126 in various cancers: a meta-analysis
2016
·
Yuanli Dong
, Chengrui Fu
, et al.
·
OncoTargets and Therapy
·
34
PDF
RETRACTED: MicroRNA-337 inhibits cell proliferation and invasion of cervical cancer through directly targeting specificity protein 1
2017
·
Wei Dong
, Baosheng Li
, et al.
·
Tumor Biology
·
27
Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations
2021
·
Jinmin Han
, Chengrui Fu
, et al.
·
Radiation Oncology
·
26
PDF
Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma
2015
·
WEI DONG
, BAOSHENG LI
, et al.
·
Oncology Reports
·
26
PDF
Reduction of inter-observer variability using MRI and CT fusion in delineating of primary tumor for radiotherapy in lung cancer with atelectasis
2022
·
Hongjiao Zhang
, Chengrui Fu
, et al.
·
Frontiers in Oncology
·
16
PDF
Integrative radiomics analysis of peri-tumoral and habitat zones for predicting major pathological response to neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer
2025
·
Dan Han
, Junfeng Zhao
, et al.
·
Translational Lung Cancer Research
·
15
Re-irradiation alternatives for recurrent high-grade glioma
2016
·
Yuanli Dong
, Chengrui Fu
, et al.
·
Oncology Letters
·
15
PDF
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study
2023
·
Chunyang Zhou
, Zijian Wang
, et al.
·
Annals of Translational Medicine
·
13
PDF
Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
2023
·
Chengxin Liu
, Hongfu Sun
, et al.
·
Frontiers in Immunology
·
12
Morphological Factors and Cardiac Doses in Whole Breast Radiation for Left-sided Breast Cancer
2015
·
Hui Guan
, Yuan-Li Dong
, et al.
·
Asian Pacific Journal of Cancer Prevention
·
10
PDF
Risk factors of esophageal fistula induced by re-radiotherapy for recurrent esophageal cancer with local primary site
2022
·
Xinran Wang
, Bing Hu
, et al.
·
BMC Cancer
·
9
PDF
Accurate location describe and management of lymph node recurrence after esophagectomy for thoracic esophageal squamous cell carcinoma: a retrospective cohort study
2024
·
Qian Zhao
, Jinglong Sun
, et al.
·
International Journal of Surgery
·
7
Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma
2016
·
Miaomiao Li
, Chengrui Fu
, et al.
·
British Journal of Radiology
·
7
Targeted nanostrategies eliminate pre-metastatic niche of cancer
2024
·
Juan Wang
, Ning Zhang
, et al.
·
Nano Research
·
5
Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): a phase II clinical trial
2026
·
Qian Zhao
, Yintao Li
, et al.
·
Signal Transduction and Targeted Therapy
·
4
PDF
Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.
2025
·
Chengixn Liu
, Wei Huang
, et al.
·
Journal of Clinical Oncology
·
3
PDF
Radiation from frequent whole-body CT scans induces systemic immunosuppression and immune activation of tumor tissue
2025
·
Jigang Dong
, Chengrui Fu
, et al.
·
Translational Oncology
·
2
Analysis of heart displacement during thoracic radiotherapy based on electrocardiograph-gated 4-dimensional magnetic resonance imaging
2023
·
Guanghui Yang
, Guanzhong Gong
, et al.
·
Journal of Thoracic Disease
·
2
PDF
Exploration of the Radiotherapeutic Clinical Target Volume Delineation for Gastric Cancer from Lymph Node Metastases
2017
·
WEI DONG
, BAOSHENG LI
, et al.
·
Anticancer Research
·
2
PDF
Concurrent chemoradiotherapy with or without simultaneous integrated boost for unresectable stage III non-small-cell lung cancer: a randomized phase II trial with exploratory EGFR and PD-L1 analyses
2026
·
Chengxin Liu
, Guanghui Yang
, et al.
·
Cancer Genetics
·
1
Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01)
2026
·
Chengxin Liu
, Yang Du
, et al.
·
Cancer Immunology Research
·
1
Stereotactic body radiation therapy for early-stage non-small cell lung cancer: a single-institutional retrospective analysis of outcomes and prognostic factors
2025
·
Chengrui Fu
, Jigang Dong
, et al.
·
Frontiers in Oncology
·
1
PDF
Whole-body CT scanning radiation improves the immune microenvironment of tumor tissues to enhance the antitumor effect of ICI
2025
·
Jigang Dong
, Ying Qi
, et al.
·
BMC Cancer
·
1
PDF
Show more works
View as search
Works count:
40
Citation count:
358
H-index:
11
I10-index:
12
Year
Topic
Type